Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

about

Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q51011218

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@en

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@nl

type

Item

label

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@en

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@nl

prefLabel

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@en

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@nl

P1476

Population pharmacokinetics of ...... ed non-small cell lung cancer.

@en

P2093

M Fukuoka

http://www.w3.org/2001/XMLSchema#string

S Iida

http://www.w3.org/2001/XMLSchema#string

T Kawanishi

http://www.w3.org/2001/XMLSchema#string

Y Emoto-Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib in previously treated non-small-cell lung cancer

Prediction of creatinine clearance from serum creatinine

Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Stability and performance of a population pharmacokinetic model.

P304

232-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12232

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25402940

http://www.w3.org/2001/XMLSchema#string